The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
The Thalassemia Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2025 | Opportunities to combine mitapivat with other therapies in clinical trials
Maria Domenica Cappellini, MD, University of Milan, Milan, Italy, comments on the potential for combining mitapivat with other therapies, such as gene therapy or luspatercept, in clinical trials. Prof. Cappellini suggests that combining mitapivat and luspatercept may increase efficacy, but notes that designing a clinical trial with these two agents will be challenging until mitapivat is registered. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is a very good question and scientifically speaking the answer is yes, because considering the mechanism of action of mitapivat, which is improving the metabolism of the red cells, so it’s increasing the energy production through the ATP. And the mechanism of action, for example, of luspatercept, I personally believe that the combination of the two will increase the efficacy, the results...
This is a very good question and scientifically speaking the answer is yes, because considering the mechanism of action of mitapivat, which is improving the metabolism of the red cells, so it’s increasing the energy production through the ATP. And the mechanism of action, for example, of luspatercept, I personally believe that the combination of the two will increase the efficacy, the results. But as you know, whenever you have two different compounds from two different companies, it will be difficult to design a proper clinical trial. It could be done as soon as – the drug luspatercept, of course, is already registered – as soon as mitapivat will be registered, I mean, we may design an independent study and do that. With gene therapy we still need to have some more data but it can be also an option.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
